Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)
University of Arizona
Nkarta, Inc.
Case Comprehensive Cancer Center
University of Maryland, Baltimore
M.D. Anderson Cancer Center
Masonic Cancer Center, University of Minnesota
University of Louisville
Dana-Farber Cancer Institute
Regeneron Pharmaceuticals
Regeneron Pharmaceuticals
University of Alabama at Birmingham
Morphotek
Rutgers, The State University of New Jersey
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Children's Hospital of Philadelphia
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)
Cellerant Therapeutics
Children's Oncology Group
National Cancer Institute (NCI)
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Children's Oncology Group
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Rutgers, The State University of New Jersey
Boston Medical Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Novartis
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
Duke University
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Enzon Pharmaceuticals, Inc.
Northwestern University
Northwestern University
Daiichi Sankyo